AbbVie's Temab-A receives two FDA Breakthrough Therapy Designations
The designations cover colorectal cancer and non-small cell lung cancer, and are the first for the drug.
GetSignal AbbVie Inc. ABBV
AbbVie said on October 7, 2026 that the U.S. Food and Drug Administration has granted two Breakthrough Therapy Designations for telisotuzumab adizutecan (Temab-A; ABBV-400) in colorectal cancer and non-small cell lung cancer.
The company said these are the first Breakthrough Therapy Designations for Temab-A and that its antibody-drug conjugate portfolio now includes four such designations. Temab-A is an investigational c-Met-directed antibody-drug conjugate with a novel topoisomerase 1 inhibitor, being studied in advanced solid tumors.
Key facts
- Drug
- Telisotuzumab adizutecan (Temab-A; ABBV-400)
- Indications
- Colorectal cancer; non-small cell lung cancer
- Designations granted
- Two
- Portfolio total
- Four Breakthrough Therapy Designations
Source: The company's release on PR Newswire, October 7, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
